Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATH-1019
- Development stage
- Preclinical
- Lead developer
- LeonaBio
- Modality
- Small Molecules
- Administration
- Intratumoral
01
Overview
ATH-1019 is a preclinical, small-molecule hepatocyte growth factor (HGF) stimulator being developed by Athira Pharma as part of its HGF/MET-targeted neuroregeneration platform for disorders of the peripheral nervous system and behavioral or neuropsychiatric indications. Preclinical characterization and corporate disclosures describe it as an orally active, brain-penetrant modulator designed to enhance HGF signaling, thereby promoting neuronal survival, synaptogenesis, and network repair analogous to Athira’s lead HGF/MET modulators but focused on peripheral nervous system and behavioral disorder applications.[1][7][9][11][13]
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on ATH-1019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATH-1019.